Gilead Hepatitis Drugs Brought In $4.55 Billion in First Quarter
Sales of Harvoni and an earlier hepatitis C drug, Sovaldi, far exceeded Wall Street expectations and made the company one of the top earners in pharmaceuticals.
from NYT > Health http://ift.tt/1GLIozl
via health&fitness
Aucun commentaire:
Enregistrer un commentaire